Health Care Commission issued a document, 10 billion class antibiotic market fear of change!

[China Pharmaceutical network industry news] on May 10th, the medical administration and medical administration bureau of the National Health Commission issued the notice on continuing to do a good job in the administration of clinical application of antimicrobial agents (g.w.b.y.f [2018] No 9 (hereinafter referred to as the notice), requiring further strengthening the administration of clinical application of antimicrobial agents Among them, the notice clearly emphasized that the management of clinical application of antibacterial drugs should be strengthened for children and other key groups To strengthen the management of clinical application of antibacterial drugs in children All regions should attach great importance to the management of clinical application of children's antibacterial drugs, and take comprehensive measures to solve the current prominent problems faced by children's use of antibacterial drugs It includes strengthening the monitoring and evaluation, establishing the monitoring system for the use of antibiotics in children's Hospital, and improving the diagnosis and treatment ability and level of children's infectious diseases To strengthen the management of clinical application of antibiotics in elderly patients and pregnant women At the same time of strengthening the clinical application management of children's antibacterial drugs, we should encourage all regions to actively explore and take effective measures to strengthen the clinical application management of antibacterial drugs according to the characteristics of the elderly patients, pregnant women and other key groups, so as to further reflect the scientific, standardized, specialized, refined and information-based management According to the analysis of the current situation of China's children's drug market in 2017, the sales volume of children's antibiotics in 2005 was 5 billion yuan, and in 2014 it has risen to 10.4 billion yuan More relevant data shows that the proportion of antibiotics in children's drug market accounts for 88% It can be seen that the market scale of antibiotics for children is huge At present, many policies have been issued to restrict the transfusion and infusion of antibiotics in outpatient clinics, but it is a loophole for children's hospitals and pediatrics For example, since August 2016, the outpatient intravenous infusion of antibiotics has been stopped in medical institutions above the second level in Changzhi City, Shanxi Province, and the outpatient intravenous infusion has been stopped in all respects since October 1 (excluding children's hospitals and pediatrics) Since July 1, 2016, more than 460 public hospitals above the second level in Jiangsu Province have stopped the intravenous infusion of antibiotics (outside the children's Hospital) to outpatients In January 2016, the health and Family Planning Commission of Zhejiang Province issued a notice to gradually stop the intravenous infusion of antibiotics to outpatients, and to completely stop the third level hospital (except children's Hospital and pediatrics) It can be seen that this document issued by the medical administration will further manage antibiotics in the field of Pediatrics The industry believes that if the hospital outpatient limit transfusion, and patients do need to take antibiotics, which leads to changes in the dosage form of antibiotics, oral antibiotics will usher in a better development opportunity However, with the continuous improvement and adjustment of the current policy, the market competition is becoming increasingly fierce, and some antibiotic companies may be eliminated Take amoxicillin and other commonly used antibiotics as an example According to the data of the State Drug Administration, there are more than 600 manufacturers of amoxicillin and azithromycin, including Baiyunshan, Huabei pharmaceutical, sunflower pharmaceutical, Shiyao group and other well-known pharmaceutical enterprises The notice made it clear that drugs with poor pharmacokinetic characteristics, more adverse reactions and insufficient evidence-based medicine will be phased out In addition, before that, the national health and Family Planning Commission required all hospitals to strictly implement the requirements of varieties and product specifications when formulating the supply catalogue of antibacterial drugs, among which the injection type of carbapenem antibacterial drugs was strictly controlled within three product specifications These policies are boosting market changes, and the well-known and powerful pharmaceutical enterprises will undoubtedly usher in good results It is also a new development opportunity for pharmaceutical companies specializing in the production of children's drugs.